entertainment -WSS

entertainment

author：leisure time 2025-09-30 00:50:04 - browse：51

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Let's speed up science by embracing open access publishing

WSS

Palantir health business leans on meeting customers’ needs

Letters to First Opinion on caregivers, digital health, and more

New research casts further doubt on a common procedure used with IVF

Shifting the focus from loneliness to social health

NIH fellows want a pay raise. Will that mean less money for grants?

Kaiser's Risant Health gobbled up Geisinger. Who is next?

leisure time

entertainment

hotspot

Medicare details structure of new drug price negotiation program

Leqembi, other new Alzheimer’s drugs require better biomarkers

Sports medicine is finally prioritizing gender equality

Oak trusses raised to roof of fire

Tori Bowie and the unacceptable rates of Black maternal death

Change Healthcare can notify patients about the breach, HHS says

After affirmative action ruling, medical educators look to 'holistic review'

It's time to get medical device identifiers over the finish line

DIEP, the 'gold standard' of breast reconstruction, is under threat

Cord blood banking comes at a high cost to babies

focus

Palantir health business leans on meeting customers’ needs

Study: Pain burden is higher in Black NFL players than white ones

Retired US general questions alleged Putin, Prigozhin meeting

Woman returns to dialysis after doctors remove transplanted pig kidney

It's time to get medical device identifiers over the finish line

Biden launches a new push to limit health care costs

focus

Wikipedia

entertainment

entertainment